Into the fold: Prion diseases are neurodegenerative disorders characterized by the accumulation in the brain of a self-replicating, misfolded isoform (PrP ) of the cellular prion protein (PrP ). No therapies are available for these pathologies. We capitalized on previously described cell-based assays to screen a library of small molecules, and identified 55, a compound capable of counteracting both prion replication and toxicity. Compound 55 may represent the starting point for the development of a completely new class of therapeutics for prion diseases.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/cmdc.201700302 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!